Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

STUDY OF THE INVOLVEMENT OF TrkB RECEPTORS IN THE ANTIHYPOXIC EFFECT OF THE NEUROPEPTIDE CYCLO-PROLYL-GLYCINE

DOI: https://doi.org/10.29296/25877313-2022-01-06
Download full text PDF
Issue: 
1
Year: 
2022

K.N. Koliasnikova Ph.D. (Biol.), FSBI «Zakusov Institute of Pharmacology» (Moscow, Russia) O.S. Grigorkevich Junior Research Scientist, FSBI «Zakusov Institute of Pharmacology» (Moscow, Russia) A.G. Alyaeva Research Scientist, FSBI «Zakusov Institute of Pharmacology» (Moscow, Russia) T.A. Gudasheva Dr.Sc. (Biol.), Professor, Corr. Memder RAS, FSBI «Zakusov Institute of Pharmacology» (Moscow, Russia) E-mail: tata-sosnovka@mail.ru

Relevance. Cycloprolylglycine (CPG) was identified as a neuropeptide in 1996. It was found to have nootropic, antihypoxic, anxiolytic, neuroprotective and analgesic activity. This complex of effects is beneficial for the development of CPG-based drugs. In this regard, the study of the mechanism of ac-tion of CPG is relevant. We have previously revealed that AMPA and TrkB receptors are involved in the anxiolytic action of CPG. Objective. Purpose of the study is to reveal the involvement of TrkB receptors in the antihypoxic effect of the neuropeptide CPG. Material and methods. The method of inhibitory pharmacological analysis using the Trk receptor blocker K252A was used. Antihypoxic activity was determined in the test of "canned" hypoxia in mice. Results. The antihypoxic effect of CPG was completely removed by a specific blocker of Trk receptors K252A. Conclusions. For the first time it was shown that TrkB receptors are involved in the antihypoxic effect of the neuropeptide cyclo-prolyl-glycine.
Keywords: 
Koliasnikova K.N.
Grigorkevich O.S.
Alyaeva A.G.
Gudasheva T.A

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Gudasheva T.A., Ostrovskaja R.U., Maksimova F.V., Chuppin A.V., Trofimov S.S., Lezina V.P., Voronina T.A., Skoldinov A.P. Topologicheskie analogi piracetama na osnove prolina i ih nootropnaja aktivnost'. Himiko-farmacevticheskij zhurnal. 1989; 23(3): 276–281.
  2. Gudasheva T.A., Boyko S.S., Akparov V.Kh., Ostrovskaya R.U., Skoldinov A.P., Rozantsev G.G., Voronina T.A., Zherdev V.P., Seredenin S.B. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Letters. 1996; 391: 149–152.
  3. Gudasheva T.A., Konstantinopol'skij M.A., Ostrovskaja R.U., Seredenin S.B. Anksioliticheskaja aktivnost' jendogennogo nootropa ciklo-prolilglicina v teste pripod-njatogo krestoobraznogo labirinta stereoselektivna. Bjulleten' jeksperimental'noj biologii i mediciny. 2001; 131(5): 547–550.
  4. Guan J., Gluckman P., Yang P., et al. Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1. Scientific reports. 2014. 4: 4388.
  5. Koljasnikova K.N., Gudasheva T.A., Nazarova G.A., i dr. Shodstvo cikloprolilglicina s piracetamom po antigipoksicheskomu i nejroprotektornomu jeffektam. Jeksper-imental'naja klinicheskaja farmakologija. 2012; 75(9): 3–6.
  6. Guan J., Singh-Mallah G., Liu K., et al. The role for cyclic Glycine-Proline, a biological regulator of insulin-like growth factor-1 in pregnancy-related obesity and weight changes. J. Biol. Regul. Homeost. Agents. 2018; 32(3): 465–478.
  7. Gudasheva T.A., Grigor'ev V.V., Koljasnikova K.N., Zamojskij V.L., Seredenin S.B. Nejropeptid cikloprolilglicin javljaetsja jendogennym polozhitel'nym moduljatorom AMRA-receptorov. Doklady Akademii nauk. 2016; 471(1): 106–108.
  8. Gudasheva T.A., Koljasnikova K.N., Antipova T.A., Seredenin S.B. Nejropeptid cikloprolilglicin uvelichivaet soderzhanie mozgovogo nejrotroficheskogo faktora v nejronal'nyh kletkah. Doklady Akademii nauk. 2016; 469(4): 492–495.
  9. Aguado-Llera D., Canelles S., Fernandez-Mendivil C., et al. Improvement in inflammation is associated with the protective effect of Gly-Pro-Glu and cycloprolylgly-cine against Aβ-induced depletion of the hippocampal somatostatinergic system. Neuropharmacology. 2019. 151. 112–126.
  10. Gudasheva T.A., Povarnina P.Ju., Koljasnikova K.N. i dr. Anksioliticheskij jeffekt nejropeptida cikloprolil-glicina oposredovan AMRA- I TrkB-receptorami; Doklady Rossijskoj akademii nauk. Nauki o zhizni. 2020; 493(1): 364–366.
  11. Koljasnikova K.N., Aljaeva A.G., Voroncova O.N., Gudasheva T.A. Izuchenie vovlechennosti AMPA-receptorov v antigipoksicheskoe dejstvie nejropeptida ciklopro-lilglicina. Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2020; 23(9): 3–8.
  12. Voronina T.A. Ostrovskaja R.U., Garibova T.L. Metodicheskie rekomendacii po doklinicheskomu izucheniju lekarstvennyh sredstv s nootropnym tipom dejstvija. V kn. Rukovodstvo po provedeniju doklinicheskih issledo-vanij lekarstvennyh sredstv. Pod obshh. red. A.N. Mironova. Chast' 1. M.: Grif i K, 2012: 276–296.
  13. Mao Q.Q., Huang Z., Zhong X.M., Xian Y.F., Ip S.P. Brain-derived neurotrophic factor signalling mediates the antidepressant-like effect of piperine in chronically stressed mice. Behav Brain Res. 2014; 261:140–145. doi: 10.1016/j.bbr.2013.12.020